Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 1438Pancreatic Neoplasms 862Carcinoma, Hepatocellular 745Stomach Neoplasms 650Colonic Neoplasms 448Rectal Neoplasms 406Esophageal Neoplasms 400Breast Neoplasms 332Carcinoma, Non-Small-Cell Lung 328Neoplasms 307Liver Neoplasms 283Cholangiocarcinoma 244Ovarian Neoplasms 243Lung Neoplasms 239Neoplasm Metastasis 237Gastrointestinal Neoplasms 219Melanoma 186Esophageal Squamous Cell Carcinoma 167Prostatic Neoplasms 166Biliary Tract Neoplasms 161Endometrial Neoplasms 143Uterine Cervical Neoplasms 130Squamous Cell Carcinoma of Head and Neck 129Head and Neck Neoplasms 114Carcinoma, Renal Cell 114Sarcoma 101Urinary Bladder Neoplasms 97Adenocarcinoma Of Esophagus 90Triple Negative Breast Neoplasms 87Anus Neoplasms 83

Interventions

trastuzumab deruxtecan 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Cisplatin 2Capecitabine 2pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × Gastrointestinal × 1 year × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06846996 2025-07-08

RECOVER

Daiichi Sankyo

Recruiting
260 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡